Allogeneic Cell Therapy Market Size, Share and Key Players Analysis 2026 to 2035
What is Allogeneic Cell Therapy Market Size?
Allogeneic Cell Therapy Market Size is valued at 1.33 Million in 2025 and is predicted to reach 4.49 Billion by the year 2035 at a 13.30% CAGR during the forecast period for 2026 to 2035.
Allogeneic Cell Therapy Market Size, Share & Trends Analysis Report By Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell, Regulatory T-Cell), By Source of Cell, By Target Indication, By Therapeutic Area, Region And Segment Forecasts, 2026 to 2035
Allogeneic Cell Therapy Market Key Takeaways:
|
Key Industry Insights & Findings from the Report:
- Enhancements in cell engineering and manufacturing processes are making allogenic cell therapies more accessible and effective.
- The increasing incidence of cancers like leukaemia and lymphoma, which can be treated with allogenic cell therapies, is a major market driver.
- North America dominated the market and accounted for a global revenue share in 2023.
- The development of allogenic cell therapies involves substantial investment in clinical trials, research, and manufacturing processes.
Global Allogeneic cell therapies use the transfer of cells from a donor to a patient. Stem cells collected from the donor whose tissue type closely matches that of the patient are predominantly utilized in allogeneic cell therapies. There are various sources to get allogeneic cells, among which blood is taken from the placenta, and the umbilical cord of newborns is the prominent source of cells for allogeneic transplants. The small volume of blood comprises a high number of cells that are eligible to multiply quickly.
Moreover, raising prevalence of chronic diseases and increasing funding for stem cell research start-ups are driving the growth of allogeneic stem cell therapy market. Currently, many companies are developing a wide range of tissue-engineered products and allogeneic cell therapies aiming to bring about an era of regenerative medicine to treat people with unmet medical needs. Additionally, a rise in the prevalence of cancer and cardiovascular diseases is expected to boost the global allogeneic stem cell therapy market. For instance, JKastrup has an ongoing Phase II clinical trial for allogeneic adipose tissue-derived stromal/stem cell therapy in patients with ischemic heart disease and heart failure.
Competitive Landscape
Some of The Key Players in The Allogeneic Cell Therapy Market:
- TCR² Therapeutics
- TiGenix (Takeda)
- Adaptimmune Therapeutics plc,
- Adicet Bio, Inc.,
- Allogene Therapeutics,
- Allogene Therapeutics,
- Artiva Biotherapeutic,
- Atara Biotherapeutics,
- Athersys, Inc.,
- BioCardia Inc.,
- Bluebird Bio,
- BlueRock Therapeutics LP,
- Bone Therapeutics,
- Capricor Therapeutics,
- Cell2Cure,
- Cellectis,
- Cellenkos,
- Cellular Biomedicine Group,
- Celularity,
- Celyad,
- Century Therapeutics,
- CHABiotech,
- CRISPR Therapeutics,
- Cynata Therapeutics,
- Cyto Therapeutics Pty Limited,
- Fate Therapeutics,
- Fate Therapeutics,
- Fundamenta Therapeutics,
- GammaDelta Therapeutics Limited,
- GC Cell,
- Hope Biosciences,
- Immunity Bio,
- Lineage Cell Therapeutics, Inc.,
- MEDIPOST,
- Mesoblast Ltd,
- Nanjing Bioheng Biotech,
- NantKwest,
- Nkarta, Inc.,
- Orca Bio,
- Organogenesis Inc.,
- Osiris Therapeutics, Inc.,
- Pluristem Therapeutics Inc,
- Poseida Therapeutics
- Regeneus,
- Stemedica Cell Technologies, Inc.,
- Stempeutics
Market Segmentation
Global Allogeneic cell therapies market is segmented on the basis of cell type, cell/tissue source, indication, and region. Based on the cell type, the market is divided into Cardiosphere-derived cells (CDCS), fibroblasts, t-cells, mesenchymal stem cells (MSCS), hematopoietic stem cells (HSCS) and others. Based on cell/tissue source, the market is segmented into skin, blood, PBC, BM and others. Based on the indication, the market is divided into acute graft-versus-host disease (gvhd), chronic ulcers and diabetic foot ulcers, osteoarthritis, crohn’s disease, cardiovascular disease, solid tumors/cancers and others (alzheimer’s disease, etc). Based on region, the maarket is studied across North America, Asia-Pacific, Europe, and LAMEA.
Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
Allogeneic Cell Therapy Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 1.33 Billion |
| Revenue Forecast In 2035 | USD 4.49 Billion |
| Growth Rate CAGR | CAGR of 13.30% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of Cell Therapy, By Source of Cell, By Target Indication, By Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Juno Therapeutics, Agios Pharmaceutical, Aurora BioPharma, Atara Biotherapeutics, AryoGen Biopharma, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Pharma, Bellicum Pharmaceuticals, bluebird bio,Calibr, Carina Biotech, CARsgen Therapeutics, Celgene Corporation, Cellectis, Cell Medica, AbbVie, Allogene Therapeutics, Amgen, Cell Design Labs, Celularity, Celyad, Fate Therapeutics, Fortress Bio, Gilead Sciences, Sorrento Therapeutics, Inc., Ziopharm,Janssen Biotech, JW Therapeutics, Medisix Therapeutics, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, and Posedia Therapeutics, and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Allogeneic Cell Therapies Market :
Allogeneic Cell Therapies Market Revenue (US$ Mn) by Type of Cell Therapy
- Virus-Specific T-Cell
- Stem Cell
- Regulatory T-Cell
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Source of Cell
- Peripheral Blood
- Bone Marrow
- Umbilical Cord Blood
- Adipose Tissue
- Placenta
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Target Indication
- Bone Disorder
- Critical Limb Ischemia
- Crohn’s Disease
- Diabetic Foot Ulcer
- Graft versus Host Disease
- Leukemia
- Lymphoma
- Myelodysplastic Syndrome
- Cytomegalovirus Infection
- Others
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Therapeutic Area
- Oncological Disorders
- Neurological Disorders
- Musculoskeletal Disorder
- Autoimmune / Inflammatory Disorders
- Post-Transplant Infections
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Region
- North America-
- US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America-
- Mexico
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Allogeneic Cell Therapy Market Size is valued at 1.33 Million in 2025 and is predicted to reach 4.49 Billion by the year 2035
The Allogeneic Cell Therapy Market is expected to grow at a 13.30% CAGR during the forecast period for 2026 to 2035.
Juno Therapeutics, Agios Pharmaceutical, Aurora BioPharma, Atara Biotherapeutics, AryoGen Biopharma, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd